XBI

XBI is in Stage 3 distribution with a medium-term bearish bias. Short-term conditions remain negative with price rejecting at the 9/21 EMA zone and overbought RSI failing to support rallies. Under the Stable strategy, execute Sell Now on any relief into resistance.

• ↑Significant ETF inflows detected last week reflect positive investor sentiment.
• ↑Broad exposure across therapeutic, diagnostic, and research firms mitigates single-stock swings.
• ↓Biotech’s high R&D costs and research failures drive sector volatility.